Phase 1 N=110 Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
Obesity
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 0; 2; 5; 6 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=263 Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
Schizophrenia · Dual Diagnosis · Psychotic Disorder
Primary: Brain Reward Circuit Activation on fMRI Scan — 0.05; 0.14; 0.18; 0.12 z-score — p=0.87
Phase 1 N=9 Detection of Graft Versus Host Disease With [18F]F-AraG
Graft Versus Host Disease
Primary: Distribution of Acute GVHD Grades (MAGIC Criteria) at Time of PET/CT Scan — 0; 2; 0; 0 Participants
Phase 1 N=31 A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Breast Cancer
Primary: Dose Limiting Toxicities — 1; 0; 3; 3 Dose limiting toxicities
Phase 1 N=63 A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
Non-alcoholic Fatty Liver Disease · Obesity
Primary: Number of Subjects With Drug-related Adverse Events (AEs) — 9; 8; 14; 5 Participants
Phase 1 N=16 A Study of [¹⁴C]-LY3484356 in Healthy Female Participants
Healthy
Primary: Part 1: Pharmacokinetics (PK): Fecal Excretion of LY3484356 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 97.3…
Phase 1 N=40 Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates
Healthy
Primary: Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Digoxin — 15.8; 18.7 Hour*nanogram per milliliter (h*ng/mL)
Phase 1 N=3 Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
Metastatic Solid Tumors · Treatment-Refractory Cancers
Primary: Maximum Tolerated Dose (MTD) at Which Dose-Limiting Toxicities (DLT) Occurred With rhIL-15 Administered in Combination With Fixed Doses of Nivolumab and Ipilimumab — 1.0…
Phase 1 N=16 The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers
HIV-1-infection on Healthy Volunteers
Primary: Change in Insulin Sensitivity in Participants From Baseline to End of Study Between Two Crossover Groups. — 7.749985; 6.286017; 8.716221; 6.815305 (mg/kg/min)
Phase 1 N=16 A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body
Healthy
Primary: Area Under the Concentration-time Curve of Repaglinide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC₀-∞) — 28100; 31200; 37300 Hours × picomoles…
Phase 1 N=14 A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of Pirfenidone in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 9597.74; 9786.78 hour *…
Phase 1 N=64 A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body
Healthy
Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 1270.92; 1320.24…
Phase 1 N=12 A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese Men
Healthy
Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) — 2070; 3740 hours*nanomoles/Liter…
Phase 1 N=15 A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 75.1; 69.3 Hours * nanomol…
Phase 1 N=64 A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body
Healthy
Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 2275.77; 2166.70…